drugset / Trial / NCT01528891
Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation
Phase 3
Completed
418 enrolled
Peter Davis
Hospira, now a wholly owned subsidiary of Pfizer · collab
RandomizedSingle-groupQuadruple-blindPrevention
Summary
To Determine The Efficacy of a Rapid Bolus Injection of Dexmedetomidine on the Incidence of Emergence Agitation in Anesthetized Children and the Cardiovascular Profile of a Rapid Bolus Injection of Dexmedetomidine.
Timeline
- Start
- 2012-01
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexmedetomidine | Other / unclassified | 0.5 ug/kg | — |
Indications
No indication recorded.